HEALWELL AI Inc. (“
HEALWELL” or the
“
Company”) (TSX: AIDX) (OTCQX: HWAIF), a data
science and AI company focused on preventative care, is pleased to
announce it has completed the previously announced acquisition of a
majority ownership position in Pentavere Research Group Inc.
(“
Pentavere”), an innovative AI health-tech
company based in Toronto, Ontario, that focuses on identifying
eligible patients for approved medications and interventions.
Pentavere has a proven track record in commercialization of
real-world evidence studies and has developed strong partnerships
with major hospital networks. Pentavere’s expertise in data
abstraction and structuring, combined with their extensive network
and experience in hospital specialist care, perfectly aligns with
HEALWELL’s commitment to improving preventative care.
This acquisition adds new high margin technology
revenue, access to multiple new key pharmaceutical company and life
sciences customers, new products, partnerships with major hospital
networks in Canada and the United States, as well as an experienced
and sophisticated AI engineering team. HEALWELL’s majority
acquisition of Pentavere further solidifies its standing as a
world-class AI technology provider. Both companies are already
working on unlocking new innovations, driving unprecedented
advancements and setting the stage for a transformative era in
digital healthcare.
The capabilities of HEALWELL and Pentavere in
combination with the Company’s partnership with WELL Health
Technologies Corp. (TSX: WELL) (“WELL”) allow
HEALWELL to accelerate its strategic roadmap and tackle high value
problems in the healthcare industry. Moreover, the expanded
capacity from adding the Pentavere team will deepen HEALWELL’s
ability to unlock the value of its partnership with WELL for the
delivery of clinical decision support capabilities to WELL’s
healthcare providers.
Dr. Alexander Dobranowski, CEO of HEALWELL,
commented on the acquisition, “We are thrilled to welcome Pentavere
to the HEALWELL family. This marks our first acquisition in the
healthcare technology space, signifying a pivotal moment in
HEALWELL history. The addition of Pentavere’s data abstraction and
structuring capabilities, combined with its access to hospitals and
expertise in hospital based medical specialities, will
significantly broaden HEALWELL’s therapeutic and disease indication
spectrum. Being one of the leading technology assets in healthcare
AI in Canada, Pentavere is a perfect example of our commitment to
revolutionizing the industry through establishing and consolidating
leading healthcare technologies.”
Mr. Aaron Leibtag, Co-Founder and CEO of
Pentavere, stated, “We are excited to be joining HEALWELL in their
mission of advancing patient outcomes through data science and AI
technologies. Partnering with HEALWELL will not only enhance the
impact of our solutions but also enable us to take a major leap
forward in introducing our ground-breaking platform to larger
healthcare networks and additional jurisdictions. We are excited
about the potential of our combined capabilities and look forward
to revolutionizing the healthcare industry together with
HEALWELL.”
Pentavere’s DARWEN™ AI technology has been
validated by some of the largest pharmaceutical companies in the
world and whose research has been published by some of the most
prestigious publications globally; adding substantially to the
growing body of evidence in support of HEALWELL’s AI technologies.
DARWEN™ enables the automation of data abstraction from
unstructured electronic medical records. With the advanced DARWEN™
platform, Pentavere has developed vital partnerships and secured
data-access agreements with major hospital networks in Canada and
the United States.
Pentavere has a validated history of delivering
impactful AI-solutions to the healthcare industry. With a strong
pedigree and commercial track record of delivering complex
AI-driven real-world evidence (RWE) studies, Pentavere’s extensive
experience working with some of the world’s largest pharmaceutical
companies underscores its reputation in the commercial sector.
Pentavere’s impressive research contributions serve as a testament
to its capabilities and adds significant credibility, particularly
in the eyes of healthcare experts, key opinion leaders and clinical
researchers.
HEALWELL has acquired a majority ownership
position of Pentavere in a combined primary and secondary
transaction, with transaction details as previously announced on
November 15, 2023. In conjunction with closing, Pentavere appointed
Dr. Alexander Dobranowski, HEALWELL’s CEO, Mr. Blake Corbet,
HEALWELL’s SVP Corporate Development, and Mr. Erik Danudjaja, Board
Director at HEALWELL, as HEALWELL’s three director nominees to
Pentavere’s board of directors.
Dr. Alexander DobranowskiChief Executive
OfficerHEALWELL AI Inc.
About HEALWELL AI
HEALWELL AI is a healthcare technology company
focused on AI and data science for preventative care. Its mission
is to improve health care and save lives through early
identification and detection of disease. As a physician-led
organization with a proven management team of experienced
executives, HEALWELL AI is executing a strategy centered around
developing and acquiring technology and clinical sciences
capabilities that complement the Company's road map. HEALWELL is
publicly traded on the Toronto Stock Exchange under the symbol
“AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn
more about HEALWELL AI, please
visit: https://healwell.ai/.
About Pentavere
Pentavere Research Group is a globally
recognized and award-winning AI digital health company that has
built a best-in-class AI engine to identify patients that are
eligible for approved medications or interventions, to improve
outcomes for patients and help drive therapy growth and
penetration. Pentavere's AI system, DARWEN™, identifies patients
that are eligible for but not receiving approved medications or
interventions, improving outcomes for patients and helping drive
appropriate therapy growth and penetration.
Forward-Looking Statements
Certain statements in this press release,
constitute "forward-looking information" and "forward-looking
statements" (collectively, "forward-looking statements") within the
meaning of applicable Canadian securities laws and are based on
assumptions, expectations, estimates and projections as of the date
of this press release. Forward-looking statements in this press
release include statements with respect to, among other things: the
expected benefits of the acquisition, including the expected
financial, strategic and synergistic benefits to HEALWELL;
anticipated benefits of revenue and new products and partnerships
resulting from the majority acquisition; the expectation that the
acquisition will provide positive benefits and opportunities
through HEALWELL's strategic alliance with WELL; and that the
combined businesses will broaden HEALWELL's therapeutic and disease
indication spectrum. Forward-looking statements are often, but not
always, identified by words or phrases such as "to become",
"improve", "growth", "ensuring", "continue", "anticipated",
"expects", "proceed", "potential", "future", "consider", "result
in", "increase", "deliver", "emerging", “is poised”, "plan",
"position", "opportunities", "expansion", "exercise", "ensure",
"achieve", "acquire", "complete", "satisfy", "entitle", "subject
to" or variations of such words and phrases or statements that
certain future conditions, actions, events or results "will",
"may", "could", "would", "should", "might" or "can" be taken, occur
or be achieved, or the negative of any of these terms.
Forward-looking statements are necessarily based upon management’s
perceptions of historical trends, current conditions and expected
future developments, as well as a number of specific factors and
assumptions that, while considered reasonable by HEALWELL as of the
date of such statements, are outside of HEALWELL's control and are
inherently subject to significant business, economic and
competitive uncertainties and contingencies which could result in
the forward-looking statements ultimately being entirely or
partially incorrect or untrue. Forward-looking statements contained
in this press release are based on various assumptions, including,
but not limited to, the following: ability for HEALWELL to realize
on expected synergies with Pentavere; the stability of general
economic and market conditions; HEALWELL's ability to comply with
applicable laws and regulations; HEALWELL's continued compliance
with third party intellectual property rights; and that the risk
factors noted below, collectively, do not have a material impact on
HEALWELL's business, operations, revenues and/or results. By their
nature, forward-looking statements are subject to inherent risks
and uncertainties that may be general or specific and which give
rise to the possibility that expectations, forecasts, predictions,
projections, or conclusions will not prove to be accurate, that
assumptions may not be correct, and that objectives, strategic
goals and priorities will not be achieved.
Known and unknown risk factors, many of which
are beyond the control of HEALWELL, could cause the actual results
of HEALWELL to differ materially from the results, performance,
achievements, or developments expressed or implied by such
forward-looking statements. Such risk factors include but are not
limited to those factors which are discussed under the section
entitled "Risk Factors" in HEALWELL's most recent annual
information form dated March 31, 2023, which is available under
HEALWELL's SEDAR+ profile at www.sedarplus.ca. The risk
factors are not intended to represent a complete list of the
factors that could affect HEALWELL and the reader is cautioned to
consider these and other factors, uncertainties and potential
events carefully and not to put undue reliance on forward-looking
statements. There can be no assurance that forward-looking
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Forward-looking statements are provided for the purpose
of providing information about management’s expectations and plans
relating to the future. HEALWELL disclaims any intention or
obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise,
or to explain any material difference between subsequent actual
events and such forward-looking statements, except to the extent
required by applicable law. All of the forward-looking statements
contained in this press release are qualified by these cautionary
statements.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai
HealWell AI (TSX:AIDX)
過去 株価チャート
から 4 2024 まで 5 2024
HealWell AI (TSX:AIDX)
過去 株価チャート
から 5 2023 まで 5 2024